A case report and analysis of skin metastasis of adenocarcinoma of gastroesophageal junction and its therapeutic outcome

doi:10.19401/j.cnki.1007-3639.2025.06.010

Abstract

CLC Number:

R735.1

LI Hao, DENG Jin, LIU Peihua, ZHANG Quanyong, CAI Zhai. A case report and analysis of skin metastasis of adenocarcinoma of gastroesophageal junction and its therapeutic outcome[J]. China Oncology, 2025, 35(6): 601-604.

Figures/Tables 6

Fig. 1

Fig. 2

Fig. 3

Fig. 4

Fig. 5

Fig. 6

References 14

[1]	AJANI J A, D’AMICO T A, BENTREM D J, et al. Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2023, 21(4): 393-422.
[2]	OBERMANNOVÁ R L, LEONG T, ESMO Guidelines Committee. ESMO clinical practice guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma[J]. ESMO Open, 2025, 10(2): 104134.
[3]	ZHANG S Q, GUO J D, ZHANG H Y, et al. Metastasis pattern and prognosis in men with esophageal cancer patients: A SEER-based study[J]. Medicine (Baltimore), 2021, 100(25): e26496.
[4]	MURPHY C M, WANG K, WACHUKU C, et al. Metastatic gastric adenocarcinoma to the cutaneous neck and chest wall[J]. SAGE Open Med Case Rep, 2024, 12: 2050313X241231515.
[5]	CULLEN G. Esophageal cancer: a case study of a rare metastatic esophageal squamous cell carcinoma[J]. Clin J Oncol Nurs, 2020, 24(4): 352-355. doi: 10.1188/20.CJON.352-355 pmid: 32678357
[6]	MIYATA M, SHIOZAKI H, IIHARA K, et al. Relationship between E-cadherin expression and lymph-node metastasis in human esophageal cancer[J]. Int J Oncol, 1994, 4(1): 61-65. pmid: 21566890
[7]	WENG W H, YIN J Y, ZHANG Y, et al. Metastasis-associated protein 1 promotes tumor invasion by downregulation of E-cadherin[J]. Int J Oncol, 2014, 44(3): 812-818.
[8]	NEMOTO M, ICHIKAWA H, NAGAHASHI M, et al. Phospho-sphingosine kinase 1 expression in lymphatic spread of esophageal squamous cell carcinoma[J]. J Surg Res, 2019, 234: 123-131. doi: S0022-4804(18)30637-1 pmid: 30527463
[9]	ZHENG S Y, ZHANG Y, GONG X Z, et al. CREB1 regulates RECQL4 to inhibit mitophagy and promote esophageal cancer metastasis[J]. J Clin Biochem Nutr, 2024, 75(2): 102-110. doi: 10.3164/jcbn.23-118 pmid: 39345293
[10]	GERDES J. Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies[J]. Semin Cancer Biol, 1990, 1(3): 199-206. pmid: 2103495
[11]	BUTERA A, AMELIO I. Deciphering the significance of p53 mutant proteins[J]. Trends Cell Biol, 2025, 35(3): 258-268.
[12]	JANIC A, ABAD E, AMELIO I. Decoding p 53 tumor suppression: a crosstalk between genomic stability and epigenetic control?[J]. Cell Death Differ, 2025, 32(1): 1-8.
[13]	GSCHNELL M, VOLBERG C, HAUSER C, et al. Cutaneous metastases: from epidemiology to therapy[J]. J Dtsch Dermatol Ges, 2024, 22(7): 974-993.
[14]	GAO Y C, ZHANG H C, TANG L, et al. Cancer nanobombs delivering artoxplatin with a polyigniter bearing hydrophobic ferrocene units upregulate PD-L1 expression and stimulate stronger anticancer immunity[J]. Adv Sci (Weinh), 2024, 11(4): e2300806.

[1]	FAN Sumei, XIN Congling, ZHU Laifang, LIU Chang, XU Rui, ZHOU Zhengrong, CHENG Xi. Effectiveness and safety analysis of camrelizumab combined with chemotherapy and targeted therapy in patients with recurrent, metastatic, and treatment-naive advanced cervical cancer: a retrospective cohort study [J]. China Oncology, 2025, 35(6): 570-577.
[2]	ZHAO Kaile, WANG Lei, GENG Jianxiong, CUI Chengwei, YU Yan. Research status and prospects of treatment for malignant pleural mesothelioma [J]. China Oncology, 2025, 35(3): 326-332.
[3]	LU Yufeng, WANG Han, XIE Yifan, JIANG Yizhou, SHAO Zhimin. Significant fundamental translational research on breast cancer in China: progress and prospects [J]. China Oncology, 2025, 35(2): 143-153.
[4]	LI Yuan, GUO Lingchuan, YUAN Yong, ZHENG Qiang, JIN Yan, MING Jian. Cost-effectiveness of PD-L1 testing to guide immunotherapy for patients with non-small cell lung cancer in China [J]. China Oncology, 2025, 35(2): 237-248.
[5]	GENG Qianqian, YANG Aimin. Progress and prospect on treatment for radioiodine-refractory thyroid cancer [J]. China Oncology, 2025, 35(1): 30-39.
[6]	LI Ruping, YANG Hui. Current status and future prospects of clinical trials for radioiodine-refractory thyroid cancer [J]. China Oncology, 2025, 35(1): 40-48.
[7]	LIN Qiuyu, WANG Yuxin, LIN Chenghe. Application and prospect of targeted therapy and immunotherapy in radioiodine-refractory differentiated thyroid cancer [J]. China Oncology, 2025, 35(1): 58-67.
[8]	XU Rui, WANG Zehao, WU Jiong. Advances in the role of tumor-associated neutrophils in the development of breast cancer [J]. China Oncology, 2024, 34(9): 881-889.
[9]	CAO Xiaoshan, YANG Beibei, CONG Binbin, LIU Hong. The progress of treatment for brain metastases of triple-negative breast cancer [J]. China Oncology, 2024, 34(8): 777-784.
[10]	LIU Shuai, ZHANG Kai, ZHANG Xiaoqing, LUAN Wei. An exploratory study on the perioperative treatment of locally advanced gastric cancer with combination of penpulimab, anlotinib and chemotherapy [J]. China Oncology, 2024, 34(7): 659-668.
[11]	LIAO Ziyi, PENG Yang, ZENG Beilei, MA Yingying, ZENG Li, GAN Kelun, MA Daiyuan. Analysis of pathological remission degree and influencing factors of radical surgery after neoadjuvant immunotherapy combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma [J]. China Oncology, 2024, 34(7): 669-679.
[12]	LIANG Yingyun, CHEN Jianhua. Application progress of oncolytic virus combined with immunotherapy in the treatment of malignant tumors [J]. China Oncology, 2024, 34(7): 686-694.
[13]	HUANG Sijie, KANG Xun, LI Wenbin. Clinical research progress of intrathecal therapy in the treatment of leptomeningeal metastasis [J]. China Oncology, 2024, 34(7): 695-701.
[14]	TANG Nan, HUANG Huixia, LIU Xiaojian. Integrated single-cell sequencing and transcriptome sequencing to reveal a 9-gene prognostic signature of immune cells in colorectal cancer [J]. China Oncology, 2024, 34(6): 548-560.
[15]	XIN Meiyi, LIN Yuhong, ZHAO Kai. Progress in the development of mRNA vaccine and its delivery systems for anti-tumor immunotherapy [J]. China Oncology, 2024, 34(5): 509-516.

A case report and analysis of skin metastasis of adenocarcinoma of gastroesophageal junction and its therapeutic outcome

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 6

References 14

Related Articles 15

Recommended Articles

Metrics

Comments